TP53 and breast cancer: Ward et al. [34] have utilized next-generation sequencing to amplify DNA from the urine of BC patients and have detected mutations with 70% sensitivity; 54% of the mutations were in TERT, 28% in FGFR3, 13% in PIK3CA, 13% in TP53, 5% in RXRA, and 1% in HRAS mutations.